Trastuzumab Deruxtecan (ENHERTU)

HER2-directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload

Trastuzumab Deruxtecan (ENHERTU)

Forms and strengths
Form: TabletStrength: 100 mg/vial (reconstituted to 20 mg/mL)
Print

Indication

  • Trastuzumab deruxtecan (ENHERTU) is used alone to treat adults with unresectable or metastatic HER2-positive breast cancer who have already received at least one prior anti-HER2 treatment regimen, either for metastatic disease or with recurrence within 6 months of completing earlier treatment.
  • It is used alone for HER2-positive breast cancer that has previously been treated with trastuzumab emtansine.
  • It is used alone for hormone receptor-positive, HER2-low or HER2-ultralow breast cancer in patients who have had at least one endocrine therapy and are no longer considered candidates for further endocrine treatment.
  • It is used alone for HER2-low breast cancer after at least one prior chemotherapy regimen for metastatic disease, or recurrence within 6 months of completing adjuvant chemotherapy.
  • It is used alone for unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after a prior trastuzumab-based treatment regimen.
  • It is used alone for unresectable or metastatic HER2-positive (IHC 3+) solid tumours in patients who have had prior systemic treatment and have no satisfactory alternative options.
  • Treatment requires laboratory confirmation of the tumour's HER2 status using a validated test before starting therapy.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.